<DOC>
	<DOCNO>NCT01251354</DOCNO>
	<brief_summary>The purpose protocol determine effect BN83495 progression endometrial cancer estrogen receptor post menopausal woman previously receive chemotherapy .</brief_summary>
	<brief_title>Study BN83495 Post-menopausal Women With Endometrial Cancer Post-chemotherapy</brief_title>
	<detailed_description />
	<mesh_term>Endometrial Neoplasms</mesh_term>
	<criteria>Provision write informed consent prior study related procedure . postmenopausal ovariectomised female patient 18 year age . histologically confirm diagnosis ER positive endometrial carcinoma primary tumour metastatic disease patient receive one line chemotherapy prior enrolment adjuvant metastatic setting ( include chemoradiotherapy ) progress line chemotherapy patient least one measurable disease site ( RECIST criterion version 1.1 ) patient receive hormone therapy endometrial cancer adjuvant metastatic setting patient receive one line chemotherapy adjuvant metastatic setting patient treat investigational agent within 3 week study entry . patient ongoing cardiac dysrhythmias grade â‰¥2 , atrial fibrillation grade ( NCI CTCAE ) QTcF interval &gt; 460 msec .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2015</verification_date>
</DOC>